Semaglutide Associated with Lower Risk of Suicidal Ideations Compared to Other Treatments Prescribed for Obesity or Type 2 Diabetes
NIH-funded analysis finds patients treated with semaglutide had 49% to 73% lower risk of suicidal ideation than those given other medications.
January 5, 2024 -- Semaglutide, a highly popular medication approved by the U.S. Food and Drug... (Source: Drugs.com - Clinical Trials)
Source: Drugs.com - Clinical Trials - January 5, 2024 Category: Pharmaceuticals Source Type: clinical trials
High-Dose Ambroxol in GBA1-Related Parkinson
Conditions: Parkinson Disease; GBA Gene Mutation Interventions: Drug: Ambroxol Hydrochloride Sponsors: Agyany Pharma LTD Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - January 5, 2024 Category: Research Source Type: clinical trials
Lapatinib Increases Overall Survival in Metastatic Breast Cancer Patients With HER2-Positive Circulating Tumor Cells
WASHINGTON, Jan. 4, 2024. A new study shows that lapatinib, a drug used for the treatment of metastatic HER2-positive cancer, is associated with improved overall survival in patients with initially HER2-negative metastatic breast cancer and... (Source: Drugs.com - Clinical Trials)
Source: Drugs.com - Clinical Trials - January 4, 2024 Category: Pharmaceuticals Source Type: clinical trials
Canadian CHO-KLAT/H-FIT Study - Quality of Life of, and Burden of Caring for, Persons With Hemophilia
Conditions: Hemophilia Sponsors: The Hospital for Sick Children; Roche Pharma AG Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - January 4, 2024 Category: Research Source Type: clinical trials
Aromatherapy for Upper Respiratory Health
Conditions: Immune System Interventions: Other: Essential oil blend; Other: Placebo Sponsors: Franklin Health Research; Prodeco Pharma Completed (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - January 4, 2024 Category: Research Source Type: clinical trials
AskBio Phase Ib Trial of AB-1005 Gene Therapy in Patients with Parkinson ’s Disease Meets Primary Endpoint
Berlin, Germany/Research Triangle Park, North Carolina, USA, January 4, 2024– Bayer AG and Asklepios BioPharmaceutical, Inc. (AskBio), a gene therapy company wholly owned and independently operated as a subsidiary of Bayer AG, announced today... (Source: Drugs.com - Clinical Trials)
Source: Drugs.com - Clinical Trials - January 4, 2024 Category: Pharmaceuticals Source Type: clinical trials
New Published Data Demonstrates Correlation Between Itch Cytokine Interleukin-31 Reduction and Pruritis Improvement in Primary Biliary Cholangitis in Phase 3 Post-Hoc Analysis of CymaBay's Seladelpar
NEWARK, Calif., Jan. 3, 2024 /PRNewswire/ -- CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a biopharmaceutical company focused on innovative therapies for patients with liver and other chronic diseases, today announced the first published findings... (Source: Drugs.com - Clinical Trials)
Source: Drugs.com - Clinical Trials - January 3, 2024 Category: Pharmaceuticals Source Type: clinical trials
Genascence Announces Initiation of Phase 1b Clinical Trial of GNSC-001 Gene Therapy for Knee Osteoarthritis
PALO ALTO, Calif., Jan. 3, 2024 Genascence Corporation ( " Genascence " ), a clinical-stage biotechnology company revolutionizing the treatment of prevalent musculoskeletal diseases with gene therapy, today announced the initiation of its... (Source: Drugs.com - Clinical Trials)
Source: Drugs.com - Clinical Trials - January 3, 2024 Category: Pharmaceuticals Source Type: clinical trials
First Patient Implanted in PIERRE IDE Clinical Study of the ThecaFlex DRx System for Administration of Spinraza
LOWELL, Mass., Jan. 3, 2024. Alycone Therapeutics Inc. (Alcyone), a biotechnology company pioneering next-generation precision genetic therapies and precision delivery solutions of therapies for complex neurological conditions, announced the first... (Source: Drugs.com - Clinical Trials)
Source: Drugs.com - Clinical Trials - January 3, 2024 Category: Pharmaceuticals Source Type: clinical trials
Anavex Life Sciences Provides an Update on ANAVEX ®2-73 Rett Syndrome Program
NEW YORK– January 2, 2024 -- Anavex Life Sciences Corp. (“Anavex” or the“Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of... (Source: Drugs.com - Clinical Trials)
Source: Drugs.com - Clinical Trials - January 2, 2024 Category: Pharmaceuticals Source Type: clinical trials
Longboard Pharmaceuticals Announces Positive Topline Data from the PACIFIC Study, a Phase 1b/2a Clinical Trial, for Bexicaserin (LP352) in Participants with Developmental and Epileptic Encephalopathies (DEEs)
Bexicaserin achieved a median seizure reduction of 53.3% in countable motor seizures compared to 20.8% in the placebo group across the DEE study population
A median seizure reduction of 72.1% in Dravet Syndrome (DS), 48.1% in Lennox-Gastaut... (Source: Drugs.com - Clinical Trials)
Source: Drugs.com - Clinical Trials - January 2, 2024 Category: Pharmaceuticals Source Type: clinical trials
First Patient, First Visit in Phase 3 Clinical Trial of Vezocolmitide for Dry Eye Disease
STUART, Fla., Dec. 29, 2023. Stuart Therapeutics, Inc. ( " Stuart " ), a clinical stage biopharmaceutical company conducting research and development of unique extracellular matrix-targeting peptide therapeutics for ophthalmic diseases, today announced... (Source: Drugs.com - Clinical Trials)
Source: Drugs.com - Clinical Trials - December 30, 2023 Category: Pharmaceuticals Source Type: clinical trials
IND Application Submitted to the FDA for a Phase 1 Clinical Trial of DA-1726 for the Treatment of Obesity
CAMBRIDGE, Mass., Dec. 28, 2023. NeuroBo Pharmaceuticals, Inc., a clinical-stage biotechnology company focused on transforming cardiometabolic diseases, today announced that it has submitted an Investigational New Drug (IND) application to the U.S.... (Source: Drugs.com - Clinical Trials)
Source: Drugs.com - Clinical Trials - December 28, 2023 Category: Pharmaceuticals Source Type: clinical trials
A Study of APG-2575 in Patients With Mild-to-moderate Systemic Lupus Erythematosus.
Conditions: SLE Interventions: Drug: APG-2575; Other: Placebo Sponsors: Ascentage Pharma Group Inc.; Suzhou Yasheng Pharmaceutical Co., Ltd. Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - December 27, 2023 Category: Research Source Type: clinical trials
First patient dosed in Phase III prostate cancer trial with Cu-64 SAR-bisPSMA
SYDNEY, Dec. 22, 2023. Clarity Pharmaceuticals (ASX: CU6) ( " Clarity " ), a clinical stage radiopharmaceutical company with a mission to develop next-generation products that improve treatment outcomes for children and adults with cancer, is pleased to... (Source: Drugs.com - Clinical Trials)
Source: Drugs.com - Clinical Trials - December 22, 2023 Category: Pharmaceuticals Source Type: clinical trials
